SELLAS Life Sciences Group (SLS) Net Income towards Common Stockholders: 2011-2023
Historic Net Income towards Common Stockholders for SELLAS Life Sciences Group (SLS) over the last 4 years, with Dec 2023 value amounting to -$8.2 million.
- SELLAS Life Sciences Group's Net Income towards Common Stockholders rose 13.43% to -$8.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$37.9 million, marking a year-over-year increase of 9.73%. This contributed to the annual value of -$37.9 million for FY2023, which is 8.31% up from last year.
- Latest data reveals that SELLAS Life Sciences Group reported Net Income towards Common Stockholders of -$8.2 million as of Q4 2023, which was up 12.65% from -$9.4 million recorded in Q3 2023.
- Over the past 5 years, SELLAS Life Sciences Group's Net Income towards Common Stockholders peaked at -$2.4 million during Q1 2021, and registered a low of -$16.7 million during Q1 2022.
- Over the past 3 years, SELLAS Life Sciences Group's median Net Income towards Common Stockholders value was -$8.4 million (recorded in 2022), while the average stood at -$8.4 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 43.07% in 2021, then crashed by 596.42% in 2022.
- Over the past 4 years, SELLAS Life Sciences Group's Net Income towards Common Stockholders (Quarterly) stood at -$3.7 million in 2020, then plummeted by 77.56% to -$6.6 million in 2021, then crashed by 43.16% to -$9.4 million in 2022, then increased by 13.43% to -$8.2 million in 2023.
- Its last three reported values are -$8.2 million in Q4 2023, -$9.4 million for Q3 2023, and -$9.1 million during Q2 2023.